Ligand commits up to $47m to back AvenCell's allogeneic CAR-T pipeline
Ligand Pharmaceuticals has entered a financing agreement with clinical-stage cell therapy company AvenCell Therapeutics worth up to $47 million, funding the development of AvenCell's allogeneic CAR-T programmes in acute myeloid leukaemia and B-cell malignancies.
Under the deal, Ligand has committed up to $41 million in royalty-bearing capital, with the applicable royalty rate set at a mid-single-digit to low-double-digit percentage of worldwide annual net sales across all current and future AvenCell pipeline assets. The precise rate will be determined by the total amount ultimately drawn. Capital will be released in four tranches: an initial payment at closing, followed by three further tranches contingent on predetermined clinical milestones and other financing conditions. Ligand has separately committed up to $6 million in a concomitant Series C equity round, details of which are expected to follow.
The programmes
AvenCell's lead candidate, AVC-201, is an anti-CD123 CAR-T cell therapy currently in a Phase 1b expansion trial for relapsed or refractory AML, one of the hardest-to-treat haematological cancers. Its second programme, AVC-203, is in Phase 1a for B-cell malignancies. Both are built on a platform that combines CRISPR/Cas9-based allogeneic engineering, originally derived from Intellia Therapeutics' technology, with a switchable CAR architecture developed by GEMoaB GmbH, now rebranded as AvenCell Europe GmbH. The switchable design is intended to give clinicians greater real-time control over CAR-T activity, a meaningful safety consideration given the cytokine release syndrome and other toxicity risks associated with approved CAR-T products.
Todd Davis, chief executive of Ligand, said AvenCell's platform combines CRISPR-engineered allogeneic technology with "a unique switchable CAR approach designed to provide greater control over CAR-T activity," and pointed to encouraging early clinical data from AVC-201 as evidence of the platform's potential across a broad range of diseases.
Market context
The royalty-financing structure Ligand deploys is increasingly common in biotech capital markets, offering companies non-dilutive capital at a stage where equity raises would be punitive while giving the financier long-dated exposure to commercial success. Ligand manages economic interests in more than 200 development and commercial-stage assets, and the AvenCell deal fits its stated strategy of targeting high-value late-preclinical and clinical-stage programmes.
Allogeneic, or "off-the-shelf," CAR-T remains one of the most competitive and technically demanding areas in oncology. Unlike autologous therapies, which require patient-specific manufacturing, allogeneic products are manufactured from donor cells in batch, making them potentially faster and cheaper to deliver. Several well-capitalised programmes are pursuing this space, including efforts using gene-editing platforms from a number of academic spinouts and larger biotechs. The key unresolved challenge is durability of response: allogeneic products face immune rejection that can limit persistence. AvenCell's switchable CAR architecture is positioned as a partial answer to that problem by enabling dose modulation post-infusion, though clinical validation at scale remains to be demonstrated.
For AML specifically, the treatment landscape after relapse is sparse and survival outcomes remain poor, which gives programmes like AVC-201 a meaningful regulatory pathway if early-phase data continue to hold. Investors and clinicians will watch for Phase 1b expansion data, including response rates and safety signals, as the next substantive readout.